Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients ON and OFF levodopa

Clinical Neuropharmacology

Volumn 25, Issue 4, 2002, Pages 216-224

  Duchesne, Nicole ^a   Soucy, Jean Paul ^a   Masson, Hélène ^a   Chouinard, Sylvain ^a   Bédard, Marc André ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Attention; Cognition; Neuroimaging; Neuropsychology; Parkinson's disease; SPECT

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; IODINE 123; LEVODOPA;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENERVATION; DOPAMINERGIC SYSTEM; HUMAN; NEUROPSYCHOLOGY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RESPONSE TIME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE;

AGED; COCAINE; COGNITION DISORDERS; CORPUS STRIATUM; DENERVATION; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEVODOPA; MALE; PARKINSON DISEASE; REACTION TIME; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036338907     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200207000-00005     Document Type: Article

References (59)

1. Cognitive function in Parkinson's disease: From description to theory
2. Cognitive deficits in Parkinson's disease
3. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease
4. Frontal cognitive function in patients with Parkinson's disease "on" and "off" levodopa
5. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients
6. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: The 15-objects test
7. High-memory scanning in Parkinson's disease: Adverse effect of levodopa
8. Dementia in Parkinson's disease is related to loss in medial substantia nigra
9. PET studies on the early and differential diagnosis of Parkinson's disease
10. Functional effects of striatal dysfunction in Parkinson disease
11. Cognitive impairment and the brain dopaminergic system in Parkinson disease
12. Impaired somatosensory discrimination of shape in Parkinson's disease: Association with caudate nucleus dopaminergic function
13. 123I]-β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
14. SPECT imaging demonstrates loss of striatal monoamine transporters in Parkinson's disease
15. 123I]-β-CIT striatal uptake correlates with symptom severity in Parkinson's disease
16. 11C-nomifensine and position emission tomography: The effects of age and Parkinson's disease
17. Relationship between striatal dopamine denervation and frontal executive tests in Parkinson's disease
18. 123I]-β-CIT SPECT and prefrontal cognitive functions in Parkinson's disease
19. Impaired simultaneous cognitive task performance in Parkinson's disease: A dopamine-related dysfunction
20. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease
21. Parkinsonism: Onset, progression and mortality
22. "Mini-mental state:" A practical method for grading the cognitive state of the patients for the clinician
23. Mental status examination for organic mental syndrome in the elderly patient
24. Development and validation of a depression screening scale: A preliminary report
25. 123I]beta-CIT
26. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease
27. 123I]β-CIT SPECT
28. Simplified multidose preparation of Iodine-123-β-CIT: A marker for dopamine transporters
29. 123I]-β-CIT binding to dopamine transporters in healthy human subjects
30. Striatal D2 receptor binding in sleep bruxism: A controlled study with Iodine-123-lodobenzamide Single Photon Emission Computed Tomography
31. The pedunculopontine nucleus in Parkinson's disease
32. Cholinergic-dependent cognitive deficits in Parkinson's disease
33. Acute and long-term administration of anticholinergics in Parkinson's disease: Specific effects on the subcortico-frontal syndrome
34. Is the mesocortical dopaminergic system involved in Parkinson disease?
35. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex ofrhesus monkey
36. Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: Effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex
37. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: Possible interactions with subcortical dopamine
38. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
39. 123I]beta-CIT: Pharmacologic characterization of brain uptake in nonhuman primates
40. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-Dopa in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase
41. L-Dopa is converted in serotonergic fiber of the striatum of the rat: A double-labeling immunofluorescence study
42. Distribution of serotonin immunoreactivity in the central nervous system of the rat. Cell bodies and terminals
43. Mapping the network for planning: A correlation PET activation study with the tower of London task
44. Abnormal basal ganglia outflow in Parkinson's disease identified with PET implication for higher cortical functions
45. Lateral asymmetry of neurotransmitters in human brain
46. Imaging dopamine receptors in the human brain by positron tomography
47. Fractal analysis of striatal dopamine re-uptake sites
48. Neuronal activity in the ventral striatum of the primate
49. Responses of monkeys' dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task
50. Biochemistry of neurotransmitters in Parkinson's disease
51. Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson's disease
52. Dual task performance and processing resource in normal subjects and patients with Parkinson's disease
53. A central executive deficit in patients with Parkinson's disease
54. Attention to action: Willed and automatic control of behavior
55. Internal versus external cues and the control of attention in Parkinson's disease
56. Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication
57. Verbal working memory deficit in Parkinson's disease
58. The effects of Parkinson's disease on the capacity to generate information randomly